Topic
Psychotropic drug
About: Psychotropic drug is a research topic. Over the lifetime, 2309 publications have been published within this topic receiving 54070 citations.
Papers published on a yearly basis
Papers
More filters
01 Jan 2015
TL;DR: Electroconvulsive therapy, bright light therapy, transcranial magnetic stimulation and vagal nerve stimulation are relatively safe and effective treatments during pregnancy if steps are taken to decrease potential risks.
Abstract: Ozet Psikotrop ilaclarin bir kisminin gebelikte kullaniminin teratojenik oldugu bilinmesine ragmen, gebelikte depresyon tedavisinde tamamen guvenli oldugu kanitlanmis bir tedavi yontemi bulun- mamaktadir. Gebelikte yeterince tedavi edilmeyen duygudurum bozukluklari hem anne hem de yenidogan icin onemli riskler olusturmaktadir. Bu yazida gebelikte depresyon tedavisinde kullanila- bilecek somatik tedaviler incelenmistir. Elektrokonvulsif tedavi, parlak isik tedavisi, transkranial manyetik stimulasyon ve vagal sinir stimulasyonu, potansiyel riskleri azaltmak icin gerekli onlemler alindiginda gebelik sirasinda nispeten guvenli ve etkili tedavilerdir. Gebelikte depresyon tedavisin- de somatik tedaviler uygulanacaginda mutlaka hastanin anlayacagi bicimde detayli bilgi verilmeli, bilgilendirilmis onami alinmalidir. Anahtar sozcukler: Depresyon, gebelik, somatik tedavi. Abstract Although some psychotropic drugs are known to be teratogenic no psychotropic drug is of proven safety for treatment of depression during pregnancy. Untreated mood disorders during pregnancy pose significant risks for mother and the newborn. This review focuses on the use of somatic tret- ments of depression during pregnancy.Electroconvulsive therapy, bright light therapy, transcranial magnetic stimulation and vagal nerve stimulation are relatively safe and effective treatments during pregnancy if steps are taken to decrease potential risks. A clear information related to the somatic treatment should be given to the patient and informed consent should be obtained.
3 citations
TL;DR: In this paper, the authors proposed a syndromic approach aimed at optimizing psychotropic treatment in people with dementia whose significant suffering derives from their thought, affective, or behavioral problems.
Abstract: A variety of medical and social factors have contributed over the last decades to the overuse of psychotropic drugs in people with dementia. One social factor is probably the frequent failure to provide adequate person-centered care, be it in the community or in institutional settings. This unfortunate reality has been reacted upon with numerous guidelines to reduce prescriptions of the most dangerous drugs (e.g., neuroleptics). Each psychotropic drug prescription can in principle be assessed around three dimensions: (a) adequate, (b) inadequate, and (c) chemical restraint. The CHemical Restraints avOidance MEthodology (CHROME) defined chemical restraint as any prescription based on organizational convenience, rather than justified with medical diagnosis. Two validation studies revealed that one of the main medical reasons of over- and miss-prescriptions was symptom-based prescription. By switching to syndrome-based prescription, a large proportion of drugs could be de-prescribed and some re-adjusted or kept. Paucity of research and weakness of data are not conclusive about the adequacy of specific drugs for the myriad of cases presented by patients with dementia and comorbid conditions. Clinical practice, however, leads us to believe that even under optimal care conditions, psychotropics might still contribute to quality of life if based on an adequate diagnosis. This article explains the rationale that underlies a syndromic approach aimed at optimizing psychotropic treatment in people with dementia whose significant suffering derives from their thought, affective, or behavioral problems. The results of previous validation studies of this new methodology will be discussed and conclusions for future results will be drawn.
3 citations
TL;DR: An automated column-switching high performance liquid chromatographic method with ultraviolet detection was described for rapid and sensitive determination of clocapramine, a psychotropic drug, and its two metabolites, clospipramine and dehydroclospipramerine, in dog and human plasmas as discussed by the authors.
Abstract: An automated column-switching high performance liquid chromatographic method with ultraviolet detection is described for rapid and sensitive determination of clocapramine, a psychotropic drug, and its two metabolites, clospipramine and dehydroclospipramine, in dog and human plasmas. The drug and the metabolites were extracted together with trifluperidol as an internal standard with a heptane-chloroform mixture from plasma. The extract was subjected to column-switching high performance liquid chromatography using a bovine serum albumin-coated cyanopropyl silica gel column, a newly developed sample clean-up column, and a reversed phase column (TSK gel ODS-80TM) for analytical separation.The detection limits (S/N=3) of clocapramine, clospipramine and dehydroclospipramine were 0.5-1.0ng ml-1.
3 citations
01 May 1978
TL;DR: Army physicians (primary care physicians and psychiatrists) performing out-patient services for troops on duty in Vietnam were surveyed in mid-1967, finding the drugs used to treat a wide range of conditions the most frequent of which were gastroenteritis and anxiety.
Abstract: : Army physicians (primary care physicians and psychiatrists) performing out-patient services for troops on duty in Vietnam were surveyed in mid-1967. Two Navy psychiatrists were also included in the survey. All were asked to report information on the psychotropic drug prescriptions they wrote during the immediately preceeding 30-day period. Less than 50 per cent of the 256 physicians who were sent questionnaires returned them. From the available data an estimate of 12.5 per cent per year was derived for the psychotropic drug prescription rate. The drugs were used to treat a wide range of conditions the most frequent of which were (a) gastroenteritis (by the primary care group) and (b) anxiety (by both physician groups). Depression was infrequently listed as the presenting condition. Primary care physicians differed from psychiatrists on several prescription variables. The drugs were perceived by the prescribers as being quite efficacious for most of the conditions treated.
3 citations
TL;DR: There is little research to support the strong involvement of placebo response as part of hypnotic responsiveness, and turf and financial motivations associated with the rise of “biological psychiatry,” are discussed.
Abstract: In an elaboration on the contribution by Raz (current issue), placebo response is further reviewed in relation to psychotropic drug research. Many therapists are unaware that placebo controlled research documents that antidepressant and anxiolytic drugs on average are only mildly more effective than a placebo. Systematic biases in research design are noted that could account for the small differences. These factors, and turf and financial motivations associated with the rise of "biological psychiatry," are discussed because they impact the practice of clinical hypnosis and psychotherapy. Although placebo research is fascinating and expectancy is certainly an important factor in hypnotic response, thus far, there is little research to support the strong involvement of placebo response as part of hypnotic responsiveness.
3 citations